Pediatric Cancer in the United States: The Children's Oncology Group Epidemiology Research Program

Open Access
Publisher Website
Google Scholar
Abstract
Over 8,500 children under age 15 years are diagnosed with cancer each year in the United States (1). Unlike adults, where epithelial tumors predominate, the most common types of cancer in children include the leukemias and lymphomas and the tumors of the central and sympathetic nervous systems, soft tissue, bone, and kidney. The overall incidence rate for childhood cancers has increased significantly by almost 33% during the period 1975 to 2001 (1), although, in more recent years, the rate has been leveling off. Only ∼5% of childhood cancers can primarily be attributed to a genetic predisposition (2). With the exception of a few known risk factors including in utero exposure to radiation and prior chemotherapeutic agents (3), the etiology of most childhood cancer is unknown. Because of its rarity, epidemiologic studies of childhood cancer are challenging. In particular, using a case-control approach necessitates careful assembly of well-characterized cases, which requires cooperation among many hospitals and institutions and the identification of a feasible and valid control group. In this editorial, we highlight the current challenges and approaches to advancing our understanding of the etiology of childhood cancer.Most previous epidemiologic studies of childhood cancer in the United States were conducted through the former Children's Cancer Group (see Table 1), which consisted of approximately half of the hospitals and institutions that treated children with cancer (4). In 2000, the Children's Oncology Group (COG), an international consortium of hospitals and institutions in the United States, Canada, and elsewhere, was established through the merger of four pediatric oncology clinical trial groups, including Children's Cancer Group, Pediatric Oncology Group, National Wilms' Tumor Study Group, and International Rhabdomyosarcoma Study Group. It is estimated that ∼90% of children diagnosed with cancer in the United States are treated by a member institution of the COG (4). In addition to an Operations Center, a Research and Statistical Data Center, a Group Chair's Office (currently, Dr. Gregory H. Reaman), and nearly 250 affiliated COG institutions who are committed to participate in therapeutic and nontherapeutic trials, scientific and discipline standing committees are charged with proposing innovative research in their respective fields.The COG Epidemiology Steering Committee (n = 12) consists of epidemiologists, molecular biologists, pediatric oncologists, nurses, and other health professionals.33Dr. Ross is Chair and Dr. Olshan is a member of the COG Epidemiology Steering Committee. Moreover, ∼30 individuals from various disciplines around the world are associate members of the committee. Several key areas for future initiatives have been identified by members, including (a) addressing important methodologic issues (including control selection and exposure assessment), (b) expanding studies of gene-environment interactions, and (c) developing educational materials. Current examples of the former two are discussed briefly below. Finally, because of the nationwide coverage of COG, a North American pediatric cancer registry is being proposed.To date, most national epidemiology studies of pediatric cancer have used random digit dialing for control selection. However, with the telemarketing burden and the increasing use of answering machines, cellular telephones, and caller identification, the efficiency of random digit dialing is decreasing. Further, concerns about the validity of this method are increasing. Our most recent experience with random digit dialing suggests overall response rates (5) of 70% could release identifying information from birth certificates. This method for control selection will be used in the expansion of the epidemiology of infant leukemia study as well as the proposed hepatoblastoma study. Further, members of the committee plan to submit a grant proposal to test and characterize the feasibility of using birth certificates for recruiting controls up to age 15 years.Childhood cancer studies are only beginning to incorporate single nucleotide polymorphisms and haplotypes into studies of gene-gene and gene-environment interactions (9-13). A few of the studies in Table 1 have and will be incorporating susceptibility markers into analyses (E14, E15, AE24, and AE27). However, these types of studies require large sample sizes. It is expected that a national pediatric cancer registry will help facilitate this type of research through the expeditious acquisition of diverse biological samples from both parents and children. The committee is hosting a workshop on gene-environment interactions in childhood cancer in October 2004 to discuss various study design issues to consider once a registry is in place.Because COG treats the vast majority of children with cancer in the United States (4), it makes sense to consider using COG as the basis for a national pediatric cancer registry. Importantly, individual institution ethical and review boards are requiring local investigators to contact and obtain signed consent forms from parents before they are approached to consider participation in COG-wide epidemiology, biology, and other nontherapeutic studies. (This is in addition to the mandatory institutional review board approval and informed consent that is required by the institution(s) and investigator(s) actually conducting the nontherapeutic study.) For COG epidemiologic studies, this can present a huge hurdle, as often with only one or two cases at a specific institution, it is necessary to obtain institutional review board approval at 200(!) or more institutions. Further, because local institutional investigators are often overworked and understaffed, there is a tendency to delay submitting nontherapeutic studies through institutional review boards and, once approved, difficulty in tracing and locating parents for consent to be...